References
- Tse E, Kwong Y-L. How I treat NK/T-cell lymphomas. Blood. 2013;121:4997–5005.
- Tse E, Kwong Y-L. The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol. 2017;10:85–97.
- Rose MG, Berliner N. T-cell large granular lymphocyte leukemia and related disorders. Oncologist. 2004;9:247–258.
- Sun H, Wei S, Yang L. Dysfunction of immune system in the development of large granular lymphocyte leukemia. Hematology. 2019;24:139–147.
- Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29:4410–4416.
- Kwong Y-L, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase. Blood. 2017;129:2437–2442.
- Chan JK, Tsang WY, Ng CS. Clarification of CD3 immunoreactivity in nasal T/natural killer cell lymphomas: the neoplastic cells are often CD3 epsilon+. Blood. 1996;87:839–841.
- Einsele H, Schrader M. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab. Ther Adv Hematol. 2016;715:299–301.
- Hsi E, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14:2775–2784.
- Tai Y, Dillon M, Song W, et al. Anti-CS1 umanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329–1337.
- Chen J, Zhong M-C, Guo H, et al. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature. 2017;544:493–497.
- Rethi B, Gogolak P, Szatman I, et al. SLAM/SLAM interactions inhibit CD40-induced production of inflammatory cytokines in monocyte-derived dendritic cells. Blood. 2006;10:821–2829.
- Kim JR, Horton NC, Mathew SO, et al. CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes. Inflamm Res. 2013;62:765–772.
- Shi J, Bodo J, Zhao X, et al. SLAMF7 (CD219/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. Br J Haematol. 2018;185:145–147.
- Nagy N, Cerboni C, Mattsson K, et al. SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines. Int J Cancer. 2000;88:439–447.
- Ishii H, Takahara M, Nagato T, et al. Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T-cell lymphoma cells by cell contact dependent interaction through membrane-bound IL-15. Int J Cancer. 2012;130:48–58.
- Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28:917–927.
- Gogishvili T, Danhof S, Prommersberger S, et al. SLAMF7-CAR T cells eliminate myeloma and confer fratricide of SLAMF + normal lymphocyte. Blood. 2017;130:2838–2847.